Elevar Therapeutics Announces FDA Acceptance of New Drug Application Filing for Rivoceranib in Combination with Camrelizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
FORT LEE, NJ, July 17, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority owned subsidiary of HLB Co., Ltd., is a fully integrated biopharmaceutical company dedicated to improving treatment experiences and patient outcomes who have limited or inadequate treatment options, announced today that the US Food and Drug Administration (FDA) has accepted a new … Read more